Core Viewpoint - The report from Guotai Haitong indicates that 2025 will be the year of commercialization for domestically developed innovative weight loss drugs with global competitiveness, following the first prescription issued for Innovent Biologics' injection of Ma Shidu peptide on July 3, marking a significant milestone in China's innovative weight loss drug development [1]. Industry Progress - Domestic innovative drug development in the weight loss sector has made substantial progress, including: - Zhongsheng Pharmaceutical completed the enrollment of all participants in the Phase III clinical trial for RAY1225 on July 31, with the first participant enrolled in June, showcasing rapid and efficient progress. The bi-weekly dosing regimen demonstrated significant advantages, with a 15.05% average weight reduction over 24 weeks in the 9mg group from Phase II study data [1]. - United BioPharma's UBT37034 received FDA IND approval, which selectively targets neuropeptide Y2 receptors to reduce weight. Preclinical studies showed that UBT37034 combined with GLP-1 analogs significantly reduced weight, outperforming other investigational drugs [1]. Company Developments - Several domestic pharmaceutical companies have made significant advancements in their weight loss drug pipelines: - LaiKai Pharmaceuticals received FDA approval for the clinical trial IND application of LAE103 on July 31, fully laying out the ActRIIA+B pathway [2]. - Gilead Sciences is expected to obtain 12-week Phase IIa data for ASC30 by Q1 2026 [2]. - Innovent Biologics' small molecule GLP-1 drug IBI3032 had its clinical trial application accepted by NMPA on July 16 [2]. - HengRui Medicine reported an average weight loss of 19.2% in the 6mg dose group during a 48-week Phase III trial, with plans to submit a new drug application soon [2]. Collaborations and Licensing - In 2023, several domestic pharmaceutical companies completed multiple licensing and collaboration deals related to weight loss drugs: - On July 30, CSPC Pharmaceutical Group licensed its oral GLP-1 small molecule SYH2086 to Madrigal Pharma for global development, production, and commercialization outside of China, with a total deal value of $2.075 billion, including a $120 million upfront payment [3]. - Borui Pharmaceutical reached a collaboration agreement with China Resources Sanjiu for the development, registration, production, and commercialization of BGM0504 injection in mainland China [3].

国产创新药对外授权交易频现大单，板块投资机会受关注。日前，恒生港股通创新药指数宣布修订编制 方案，明确剔除CXO公司，修订规则将于8月11日生效，该指数将成为ETF跟踪的指数中首批"纯度"达 100%的创新药指数。作为市场上唯一跟踪该指数的ETF，恒生创新药ETF（159316）已连续14个交易日 获净流入，产品份额连创新高，可助力投资者一键布局前沿创新药企。 近期，我国多家创新药公司达成大额专利授权交易。7月30日，石药集团与Madrigal达成全球授权协 议，含1.2亿美元预付款和最高19.55亿美元里程碑付款，同日中国生物制药公告全资附属公司与默沙东 LM-299/MK-2010项目合作进展顺利，将于近期收到3亿美元技术转移里程碑付款。7月28日，恒瑞医药 公告与英国制药巨头葛兰素史克达成一项总潜在金额达125亿美元的License out合作，涵盖12个创新药 项目。 A股港股午后均大幅反弹，港股创新药板块震荡上行，截至14:38，恒生港股通创新药指数上涨0.3%， 云顶新耀上涨9.2%，晶泰控股上涨6.8%，四环医药上涨4.6%，恒生创新药ETF（159316）盘中成交额 超4亿元。 ...

格隆汇8月4日｜港股三大指数低开高走，恒生科技指数拉升涨至0.93%，并且止步7连跌行情，恒生指 数、国企指数分别上涨0.49%及0.51%，二者亦止步4连跌行情，市场连续回调后明显出现止跌行情。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 盘面上，作为市场风向标的大型科技股多数拉升上涨，其中，快手涨3.5%，小米涨2.25%，腾讯涨 1.8%，网易涨超1%，百度飘红，阿里巴巴、美团、京东小幅下跌；美联储降息预期不断升温，提振了 黄金的吸引力，花旗上调未来0-3个月金价预测至3500美元，黄金股全线走强，山东黄金(600547)、赤峰 黄金(600988)涨近9%，招金矿业涨7.6%；中国直-10ME列装巴基斯坦军队，军工股表现活跃，半导体芯 片股拉升，与英伟达达成合作，英诺赛科涨超12%领衔。 另一方面，特朗普要求降低药品价格，连续上涨的生物医药股普遍回调，创新药概念 ...

Market Overview - The Hong Kong stock market showed a mixed performance with the Hang Seng Index rising by 0.49% to 24,627.25 points, the Hang Seng Tech Index increasing by 0.93% to 5,447.62 points, while the Red Chip Index fell by 0.16% to 4,194.29 points [1] - Major technology stocks experienced gains, with Kuaishou up over 3%, Xiaomi up over 2%, Tencent up 1.8%, and Netease up over 1% [1] - The expectation of a Federal Reserve interest rate cut has boosted the attractiveness of gold, leading Citigroup to raise its gold price forecast to $3,500 for the next 0-3 months [1] Company News - PCCW (00008.HK) reported a revenue of HKD 18.922 billion for the first half of the year, a year-on-year increase of 7%, but recorded a net loss of HKD 0.445 billion, narrowing by 4% [2] - Xinyi Solar (00968.HK) reported a revenue of HKD 10.932 billion, a decrease of 6.5% year-on-year, with a net profit of HKD 0.746 billion, down 58.8% [3] - Xinyi Glass (00868.HK) reported a revenue of HKD 9.821 billion, a decrease of 9.7% year-on-year, with a net profit of HKD 1.013 billion, down 59.6% [3] - Xinyi Energy (03868.HK) reported a revenue of HKD 1.21 billion, an increase of 7.7% year-on-year, with a net profit of HKD 0.45 billion, up 23.4% [4] - DTXS (02510.HK) issued a profit warning, expecting a mid-term net profit of approximately USD 180-200 million, a year-on-year increase of about 220% to 255% [5] - Lianhua Supermarket (00980.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 25-55 million [6] - Foton Industrial (00420.HK) issued a profit warning, expecting a mid-term net profit of HKD 30.7 million, turning from loss to profit [7] - Hong Kong Travel (00308.HK) issued a profit warning, expecting a mid-term net loss exceeding HKD 70 million, turning from profit to loss [9] - Great Wall Motors (02333.HK) reported cumulative vehicle sales of approximately 674,200 units in the first seven months, a year-on-year increase of 3.57% [10] - BYD (01211.HK) reported cumulative sales of approximately 2.4903 million new energy vehicles in the first seven months, a year-on-year increase of 27.35% [12] - Tibet Water Resources (01115.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 36 million, a year-on-year increase of about 300% [13] - Poly Property (00119.HK) issued a profit warning, expecting a mid-term net profit to decline by 40%-50% year-on-year [11] Analyst Insights - Huatai Securities noted that the recent pullback in the Hong Kong stock market is primarily due to adjustments in internal and external expectations, but the medium-term liquidity easing logic remains unchanged [14] - Dongwu Securities expressed concerns about rising overseas risks, particularly regarding the appreciation of USD assets and the approaching deadline for tariff negotiations [14] - CITIC Securities observed an increasing confidence trend in certain sub-sectors, with upward revisions in earnings expectations ahead of financial disclosures, particularly in the new energy vehicle and semiconductor sectors [15] - Ping An Securities highlighted the low valuation of the Hong Kong stock market and the increasing trading activity under the "profit-making effect," maintaining an optimistic outlook for the medium to long term [15]

港股三大指数低开高走，恒生科技指数拉升涨至0.93%，并且止步7连跌行情，恒生指数、国企指数分 别上涨0.49%及0.51%，二者亦止步4连跌行情，市场连续回调后明显出现止跌行情。盘面上，作为市场 风向标的大型科技股多数拉升上涨，其中，快手涨超3%，小米涨超2%，腾讯涨1.8%，网易涨超1%， 百度飘红，阿里巴巴、美团、京东小幅下跌；美联储降息预期不断升温，提振了黄金的吸引力，花旗上 调未来0-3个月金价预测至3500美元，黄金股全线走强，山东黄金涨超8%，招金矿业、赤峰黄金涨超 8%；中国直-10ME列装巴基斯坦军队，军工股表现活跃，半导体芯片股拉升，与英伟达达成合作，英 诺赛科涨超11%领衔。另一方面，特朗普要求降低药品价格，连续上涨的生物医药股普遍回调，创新药 概念股方向跌幅居前，康方生物、药明康德、石药集团、复星医药皆下跌，汽车股、钢铁股、石油股多 数走低。(格隆汇) ...

聚焦资本市场创新"赛道" 编者按 在资本市场中，行业板块的动态一直是投资者关注的焦点。近期，创新药、CPO概念（算力）与半导体、人工智能等板块热度居高不下，创新"赛道"备受 市场关注。创新药关乎人类健康与医疗进步，在政策扶持、技术突破下蓬勃发展，具备全球竞争力的企业将通过差异化创新和国际化布局打开成长天花 板；受益于全球AI算力需求爆发及技术迭代加速，CPO概念板块下半年将维持高景气度；人工智能行业进入快速发展期，技术的深度应用推动相关企业商 业化发展，盈利整体增加。本期《资本市场》聚焦创新行业，以期为市场提供有价值的参考。 | 数读市场 | | --- | | 8月1日,A股震荡走低,英伟达产业链调整,创新药、 | | 中药题材继续强势,AI硬件、应用概念股此消彼长。截 | | 至收盘,上证指数报3559.95点,深证成指报10991.32 | | 点。 | | 7月28日至8月1日,A股市场整体呈现回调态势,多数宽 | | 基指数下跌。Wind百大概念指数上涨比例43%。在板块 | | 方面,仅19%板块获得正收益,医药生物、通信、传媒 | | 相对表现良好,分别上涨2.95%、2.54%、1.13%。 ...

接受中国经济时报记者采访的业内人士表示，近年来，人工智能行业进入快速发展期，人工智能技术的深度应用推动相关企业的商业化发展，也带来算力 需求急剧增加，行业市场规模不断拓展、盈利整体增加。 编者按 在资本市场中，行业板块的动态一直是投资者关注的焦点。近期，创新药、CPO概念（算力）与半导体、人工智能等板块热度居高不下，创新"赛道"备受 市场关注。创新药关乎人类健康与医疗进步，在政策扶持、技术突破下蓬勃发展，具备全球竞争力的企业将通过差异化创新和国际化布局打开成长天花 板；受益于全球AI算力需求爆发及技术迭代加速，CPO概念板块下半年将维持高景气度；人工智能行业进入快速发展期，技术的深度应用推动相关企业商 业化发展，盈利整体增加。本期《资本市场》聚焦创新行业，以期为市场提供有价值的参考。 ■中国经济时报记者 孙兆 随着上市公司陆续披露业绩预告，A股半年报行情正式启幕。2025年上半年，A股人工智能板块表现出了强劲的发展态势。截至7月28日，A股人工智能板 块中有21家企业发布了2025年中报预报，其中17家预计上半年净利润同比实现正增长，占比近81%。而从净利润中值来看，上述21家公司2025年上半年整 体实现净 ...

晨会纪要（2025/08/04） 编辑人 崔健 022-28451618 SAC NO：S1150511010016 cuijian@bhzq.com 渤海证券研究所晨会纪要（2025.08.04） 宏观及策略研究 维稳当下，谋篇布局——2025 年 8 月宏观经济月报 固定收益研究 把握阶段性修复行情——利率债 8 月投资策略展望 行业研究 恒瑞医药与 GSK 达成大额合作，关注创新产业链——医药生物行业周报 证 券 研 究 报 告 晨 会 纪 要 请务必阅读正文之后的声明 渤海证券股份有限公司具备证券投资咨询业务资格 1 of 6 晨会纪要（2025/08/04） 宏观及策略研究 维稳当下，谋篇布局——2025 年 8 月宏观经济月报 周喜（证券分析师，SAC NO：S1150511010017） 宋亦威（证券分析师，SAC NO：S1150514080001） 严佩佩（证券分析师，SAC NO：S1150520110001） 靳沛芃（研究助理，SAC NO：S1150124030005） 1、海外经济及政策环境 美国方面，虽然二季度消费和投资分项偏弱，但总体经济仍在进口拖累减弱帮助下表现出韧性，通胀数据 ...

Group 1 - Hong Kong pharmaceutical and medical concept stocks declined, with Kangfang Biotech and MicroPort Medical dropping over 4%, Ping An Good Doctor down over 3%, and WuXi Biologics, WuXi AppTec, and CSPC Pharmaceutical falling over 2% [1] - Multiple Hong Kong medical and innovative drug-related ETFs fell by more than 2% due to market influences [1] Group 2 - Analysis indicates that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with procurement amounts from January to May nearing the total for the entire year of 2024, demonstrating the competitiveness of China's innovative drugs in the international market [2] - The trend of large multinational pharmaceutical companies accelerating the procurement of innovative drug patents from China is expected to continue in the medium to long term [2]

Group 1 - The core viewpoint of the news highlights a positive economic backdrop with the U.S. reaching trade agreements with the EU, Japan, and South Korea, involving a 15% tariff and significant investments into the U.S. market [1] - The U.S. stock market, particularly the S&P 500 and Nasdaq 100, has been reaching new highs, driven largely by major tech companies like Nvidia, Meta, and Microsoft, which contributed significantly to the market's gains this year [1] - The article notes that 60% of the S&P 500's gains and 50% of the Nasdaq 100's gains this year are attributed to these tech giants, raising concerns about their high forward price-to-earnings (P/E) ratios [1] Group 2 - In the A-share market, the margin financing and securities lending balance surged to 1.98 trillion, indicating a highly enthusiastic market environment with funds shifting from dividend ETFs to sectors like steel and coal [2] - The article describes a strong recovery logic in trading, with a pattern of buying on dips becoming apparent as investors share their profits in various groups [2] - The Hong Kong stock market is experiencing a rotation of funds, with new competition emerging in the food delivery sector, while some consumer stocks are showing weakness [3] Group 3 - The article discusses the performance of various account sizes in the market, revealing that a significant percentage of accounts are experiencing losses, particularly among smaller accounts, while larger accounts show a higher percentage of profitability [3] - The recent performance of pharmaceutical stocks in Hong Kong, such as CSPC Pharmaceutical Group, is highlighted, with several companies reaching year-to-date highs [3] Group 4 - The article reflects on investment strategies, emphasizing the importance of stock selection, valuation, and timing, suggesting that a simple approach can often be more effective than complex models [5][6] - It discusses the significance of valuation over technical indicators, recommending the use of historical P/E ratios for stable industries and the Shiller P/E for cyclical industries [6] - The article concludes with a perspective on investment timing, stressing that staying in the market is more crucial than trying to time market entry and exit [6]